Introduction: For patients with clinically negative axilla, sentinel lymph node biopsy (SLNB) is the standard method for axillary staging Because the SLBNs are the only positive nodes in approximately 40-70% of patients with pathologically proven positive axillae after completion axillary lymph node dissection (ALND), the treatment of patients with a positive SLBN has been reconsidered and the development of predictive tools that select the patients whom routine ALND could be avoided safely. Purpose: to characterize the patients in whom completion ALND can be avoided in spite of positive SLNB. Patients and methods: This retrospective study included all patients who had SLNB at The characteristics of the special group with positive SLNB and node-negative upon completion ALND were studied. Results: out of 66 patients with clinically negative axillae, SLNB was negative in 36 patients, with no more ALND, J Cancer Sci Clin Ther 2020; 4 (1): 001-014 Journal of Cancer Science and Clinical Therapeutics 2 and SLNB was positive in 30 patients for whom completion ALND was done, and revealed that 63.4% (19 out of 30 patients) had no other positive nodes after completion ALND. Conclusion: In patients with clinically negative axillae and positive sentinel SLNB, A combination of multiple predictive parameters as, the number of positive SLNs, the ratio between metastatic SLNs and total number of SLN retrieved, extracapsular invasion, and lymphovascular invasion were significant predictors for the risk of non-SLN involvement and can identify the patients with positive SLNB for whom routine ALND could be safely avoided.
Introduction
Staging of the axilla is one of the most prognostic factors, for prognosis and local control in patients with breast [1] .
For patients with negative axilla clinically and radiologically, sentinel lymph node biopsy (SLNB) is the standard method of staging of the axilla with less morbidity than axillary lymph node dissection (ALND) [2] . Falsenegative result is one of the drawbacks of SLNB, which may increase the risk for axillary recurrence. However, despite of about 5 to 10 percent false-negative rate with SLNB found in studies in which completion ALND has been done, several studies still conclude that axillary recurrence rates are low after a negative SLNB alone in early-stage breast cancer patients [3] . SLNB is highly accurate in patients with early tumors due to the low risk of axillary metastases, and no reports of false-negative SLN biopsy for lesions less than 1.5 cm [4] . Because the SLNs are the only positive nodes in approximately 40-70% of patients with pathologically proven positive axillae after completion ALND, the treatment of patients with a positive SLN has been reconsidered and the development of predictive tools that select the patients whom routine ALND could be avoided safely [5] . image of the field and to assess radio-active uptake by the SLN(s) this take nearly 60-120 seconds ( Figure 1 ). Then this detector was placed nearer to the field to precisely locate the detected SLN uptake using a cross laser pointer on the field that is matched to the hotspot on the camera screen and this site of laser cross is marked. Confirmation of the proper site of the SLN using the gamma probe, after scanning internal mammary region, infraclavicular region and axilla ( Figure 2 ). With field sterilization the detector of mobile gamma camera was sterile-draped in such a way as to allow placement and movement above and within the surgical field. Surgical incision was done guided by the marked site. In some cases when the breast tumor was too close to the SLN, we have a radio-active shine through effect and we couldn`t differentiate which is which, we used the portable gamma camera hiding option to hide the radio-activity of the tumor for better visualization of the SLN. After incision the hand held gamma probe was used to detect the lymph node with high tracer uptake in (SLN) ( Figure 3 ). After retrieval of SLN, then it was imaged again using gamma camera and gamma probe to be sure that it`s the SLN(s) ( Figure 4 ). The surgical field is checked again using the mobile gamma camera and hand held gamma probe to be sure that all radio-active nodes have been removed. The retrieved SLN(s) was sent for frozen section.
Method
The SLN(s) was send finally for paraffin section for the final pathology result. 
Blue Dye
Patent blue dye is injected subdrmally in circumareolar region, once the patient is asleep in theatre. This dye travels to and stains the sentinel nodes blue, thereby assisting the surgeon to find the correct lymph nodes ( Figure 5 ). The retrieved SLN(s) was sent for frozen section. The SLN(s) was send finally for paraffin section for the final pathology result ( Figure 6 ).
Results
A total of 66 patients who presented with clinically negative nodes, underwent SLN biopsy. According to Frozen section results of detected SLN(s):
-SLNB was negative in 36 patients out of 66, for all of them SLNB was enough with no more axillary dissection.
-SLNB was positive in 30 patients for whom ALND was done and the number of SLN taken as a biopsy was ≤ 2 except in 2 patients who had 3 SLNs taken.
SLNB characteristics
ALND was done in patients with positive SLNB and revealed that 63.4% (19 out of 30 patients) had no other positive nodes after completion ALND in the final pathology results (group 1) in spite of, the number of lymph nodes that were dissected, ranged from 9-21 lymph nodes.
Among those, 12 patients had only one positive sentinel node & 6 patients had two positive sentinel nodes and one had three positive sentinel nodes (Table 1A) . It has been found that 36.6% (11patients) had other positive nodes after completion ALND in the final pathological results (group 2) Among those, 7 patients had only one positive sentinel node & 3 patients had two positive sentinel nodes and one had three positive sentinel nodes (Table 1B) . In group 1: Ratio of positive SLN to total number of SLN was =1 in 10 patients (52.6%) and ˂ 1 in 9 patients (47.4%) ( Figure   7 ).
No. of +ve SLN. No. of patients with -ve non-SLN (completion ALND)

In group 2:
Ratio of positive SLN to total number of SLN was =1 in 10 patients (90.9%) and ˂ 1 in one patient %) ( Figure 7 ). In group 1: Patients' age ranged from 35-66 years with the mean age at 52.5 Among these patients 57.9 % (11 patients) were post-menopausal while 42.1% (8 patients) were premenopausal ( Figure 9 ).
In group 2: Among these patients 54.5% (6 patients) were post-menopausal, 45.5% (5 patients) were premenopausal ( Figure   9 ). Patients & tumour characteristics were illustrated in Table 4 . In group 1: Hormonal status were done to all patients with ER positive found in 78.9% of the patients (Figure 14 ), PR positive in 63.2% (Figure 15 ), negative HER 2neu in 73.7% ( Figure 16) 
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In group 2: Hormonal status were done to all patients with ER positive found in 81.8% of the patients (Figure 14) , PR positive in 81.8% (Figure 15 ), negative HER 2neu in 36.4% ( Figure 16 ) and KI 67 is high in 4 patients 36%. 
Discussion
SLNB has become the cornerstone in evaluation of axillary lymph node status instead of the conventional ALND with significant lower morbidity. SLNB is a staging modality rather than a therapeutic technique, and it is mainly depends on surgical and pathologic accuracy, with a low falsenegative rate [5] . Because the SLNs are the only positive nodes in approximately 40-70% of patients with pathologically proven positive axillae after completion ALND, the treatment of patients with a positive SLN has been reconsidered and the development of predictive tools that select the patients whom routine ALND could be avoided safely [5] . In this study, more than 63.4% of our patients with a positive SLNs had no other positive nodes in ALND suggesting that the majority of patients with positive SLNs did not benefit from ALND. Based on these results, it has been found that, the number of SLN, the proportion of completion ALND) and the surgical decision based mainly on the status of the axilla itself [8] . Multivariate analysis also showed that primary tumor size also significantly influenced the risk of non-SLN involvement, the risk was 0% in patients with pT1a, b tumors, 17% in those with pT1c tumors, and 67% in those with tumors measuring more than 20 mm. In the series of 157 cases published by Chu et al., the rate of non-SLN( completion ALND) involvement increased from 13 to 38% from stage T1b to stage T2 tumors [12] . Results of this study are in keeping with those reported in the Z0011 trial which did not demonstrate an advantage for completion ALND in patients with early breast cancer who had 1-2 positive SLNs [16] .
As 
Conclusion
In patients with early breast cancer with clinically negative axillary lymph nodes and positive sentinel lymph nodes by frozen section, it has been found that the number of positive SLNs, the ratio between metastatic SNs and total number of sentinel lymph nodes retrieved, extracapsular invasion, and lymphovascular invasion were significant predictors for the risk of non-SLN involvement. Combination of these predictive parameters can identify patients with a positive SLNB for whom routine ALND could be safely avoided.
